• Je něco špatně v tomto záznamu ?

Multiplex Protein Biomarker Profiling in Patients with Familial Hypercholesterolemia

D. Dlouha, M. Blaha, E. Rohlova, JA. Hubacek, V. Lanska, J. Visek, V. Blaha

. 2021 ; 12 (10) : . [pub] 20211012

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22012097

Familial hypercholesterolemia (FH), is an autosomal dominant disorder caused by mutations in the LDLR, APOB, PCSK9, and APOE genes and is characterized by high plasma levels of total and low-density lipoprotein (LDL) cholesterol. Our study aimed to analyze the influences of two different therapies on a wide spectrum of plasma protein biomarkers of cardiovascular diseases. Plasma from FH patients under hypolipidemic therapy (N = 18; men = 8, age 55.4 ± 13.1 years) and patients under combined long-term LDL apheresis/hypolipidemic therapy (N = 14; men = 7; age 58.0 ± 13.6 years) were analyzed in our study. We measured a profile of 184 cardiovascular disease (CVD) associated proteins using a proximity extension assay (PEA). Hypolipidemic therapy significantly (all p < 0.01) influenced 10 plasma proteins (TM, DKK1, CCL3, CD4, PDGF subunit B, AGRP, IL18, THPO, and LOX1 decreased; ST2 increased). Under combined apheresis/hypolipidemic treatment, 18 plasma proteins (LDLR, PCSK9, MMP-3, GDF2, CTRC, SORT1, VEGFD, IL27, CCL24, and KIM1 decreased; OPN, COL1A1, KLK6, IL4RA, PLC, TNFR1, GLO1, and PTX3 increased) were significantly affected (all p < 0.006). Hypolipidemic treatment mainly affected biomarkers involved in vascular endothelial maintenance. Combined therapy influenced proteins that participate in cholesterol metabolism and inflammation.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22012097
003      
CZ-PrNML
005      
20220506130839.0
007      
ta
008      
220425s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/genes12101599 $2 doi
035    __
$a (PubMed)34680994
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Dlouha, Dana $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Videnska 1958/9, 140 21 Prague, Czech Republic $1 https://orcid.org/0000000171671336
245    10
$a Multiplex Protein Biomarker Profiling in Patients with Familial Hypercholesterolemia / $c D. Dlouha, M. Blaha, E. Rohlova, JA. Hubacek, V. Lanska, J. Visek, V. Blaha
520    9_
$a Familial hypercholesterolemia (FH), is an autosomal dominant disorder caused by mutations in the LDLR, APOB, PCSK9, and APOE genes and is characterized by high plasma levels of total and low-density lipoprotein (LDL) cholesterol. Our study aimed to analyze the influences of two different therapies on a wide spectrum of plasma protein biomarkers of cardiovascular diseases. Plasma from FH $a Familial hypercholesterolemia FH is an autosomal dominant disorder caused by mutations in the LDLR APOB PCSK9 and APOE genes and is characterized by high plasma levels of total and low density lipoprotein LDL cholesterol Our study aimed to analyze the influences of two different therapies on a wide spectrum of plasma protein biomarkers of cardiovascular diseases Plasma from FH patients u $a Familial hypercholesterolemia (FH), is an autosomal dominant disorder caused by mutations in the LDLR, APOB, PCSK9, and APOE genes and is characterized by high plasma levels of total and low-density lipoprotein (LDL) cholesterol. Our study aimed to analyze the influences of two different therapies on a wide spectrum of plasma protein biomarkers of cardiovascular diseases. Plasma from FH patients under hypolipidemic therapy (N = 18; men = 8, age 55.4 ± 13.1 years) and patients under combined long-term LDL apheresis/hypolipidemic therapy (N = 14; men = 7; age 58.0 ± 13.6 years) were analyzed in our study. We measured a profile of 184 cardiovascular disease (CVD) associated proteins using a proximity extension assay (PEA). Hypolipidemic therapy significantly (all p < 0.01) influenced 10 plasma proteins (TM, DKK1, CCL3, CD4, PDGF subunit B, AGRP, IL18, THPO, and LOX1 decreased; ST2 increased). Under combined apheresis/hypolipidemic treatment, 18 plasma proteins (LDLR, PCSK9, MMP-3, GDF2, CTRC, SORT1, VEGFD, IL27, CCL24, and KIM1 decreased; OPN, COL1A1, KLK6, IL4RA, PLC, TNFR1, GLO1, and PTX3 increased) were significantly affected (all p < 0.006). Hypolipidemic treatment mainly affected biomarkers involved in vascular endothelial maintenance. Combined therapy influenced proteins that participate in cholesterol metabolism and inflammation.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a anticholesteremika $x terapeutické užití $7 D000924
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a krevní proteiny $x klasifikace $x genetika $x izolace a purifikace $7 D001798
650    _2
$a kardiovaskulární nemoci $x krev $x farmakoterapie $x genetika $x patologie $7 D002318
650    _2
$a cholesterol $x krev $x metabolismus $7 D002784
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a hyperlipoproteinemie typ II $x krev $x farmakoterapie $x genetika $x patologie $7 D006938
650    _2
$a zánět $x krev $x genetika $x metabolismus $7 D007249
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Blaha, Milan $u 4th Department of Internal Medicine-Hematology, Faculty of Medicine in Hradec Králové, University Hospital Hradec Králové and Charles University, 500 05 Hradec Králové, Czech Republic
700    1_
$a Rohlova, Eva $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Videnska 1958/9, 140 21 Prague, Czech Republic $u Laboratory of Gene Expression, Institute of Biotechnology CAS, BIOCEV, 252 50 Vestec, Czech Republic $u Department of Anthropology and Human Genetics, Faculty of Science, Charles University, 120 00 Prague, Czech Republic
700    1_
$a Hubacek, Jaroslav A $u Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Videnska 1958/9, 140 21 Prague, Czech Republic $u First Faculty of Medicine, Charles University, 128 00 Prague, Czech Republic $1 https://orcid.org/0000000165371353
700    1_
$a Lanska, Vera $u Statistical Unit, Institute for Clinical and Experimental Medicine, 140 21 Prague, Czech Republic
700    1_
$a Visek, Jakub $u 3rd Department of Internal Medicine-Metabolism and Gerontology, Faculty of Medicine in Hradec Králové, University Hospital Hradec Králové and Charles University, 500 05 Hradec Králové, Czech Republic
700    1_
$a Blaha, Vladimir $u 3rd Department of Internal Medicine-Metabolism and Gerontology, Faculty of Medicine in Hradec Králové, University Hospital Hradec Králové and Charles University, 500 05 Hradec Králové, Czech Republic $1 https://orcid.org/0000000180889919 $7 xx0002944
773    0_
$w MED00174652 $t Genes $x 2073-4425 $g Roč. 12, č. 10 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34680994 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130832 $b ABA008
999    __
$a ok $b bmc $g 1789616 $s 1163298
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 12 $c 10 $e 20211012 $i 2073-4425 $m Genes $n Genes $x MED00174652
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace